Which of the following is NOT a first-line therapy for ITP?

Which of the following is NOT a first-line therapy for ITP?

• A. Splenectomy
• B. Corticosteroids
• C. IVIg
• D. Rituximab

Answer: (A)

In immune thrombocytopenia, initial management aims to raise platelets quickly using non-surgical therapies, so the first-line choices are medical rather than surgical. Corticosteroids (like prednisone or dexamethasone) are used to dampen immune destruction of platelets and typically produce a rapid rise in count. Intravenous immunoglobulin (IVIg) can also quickly boost platelets but effect is usually temporary. These medical therapies are chosen first to gauge response and control bleeding risks without committing to surgery. Splenectomy, while it can lead to durable remission for many patients, is an invasive surgical procedure. It is reserved for after initial medical therapy has been tried and either failed or the disease has relapsed, making it a second-line option in most treatment algorithms. Because splenectomy permanently removes a major site of platelet destruction and antibody production but carries risks such as surgical complications and lifelong increased susceptibility to certain infections, it isn’t used as the initial treatment. Rituximab, a monoclonal antibody, is also not typically used as first-line therapy; it’s generally considered in the second-line setting for chronic or refractory ITP when steroids and/or IVIg are not sufficient or feasible.

In immune thrombocytopenia, initial management aims to raise platelets quickly using non-surgical therapies, so the first-line choices are medical rather than surgical. Corticosteroids (like prednisone or dexamethasone) are used to dampen immune destruction of platelets and typically produce a rapid rise in count. Intravenous immunoglobulin (IVIg) can also quickly boost platelets but effect is usually temporary. These medical therapies are chosen first to gauge response and control bleeding risks without committing to surgery.

Splenectomy, while it can lead to durable remission for many patients, is an invasive surgical procedure. It is reserved for after initial medical therapy has been tried and either failed or the disease has relapsed, making it a second-line option in most treatment algorithms. Because splenectomy permanently removes a major site of platelet destruction and antibody production but carries risks such as surgical complications and lifelong increased susceptibility to certain infections, it isn’t used as the initial treatment.

Rituximab, a monoclonal antibody, is also not typically used as first-line therapy; it’s generally considered in the second-line setting for chronic or refractory ITP when steroids and/or IVIg are not sufficient or feasible.